anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In 2019, three regulations of the Minister of Health regarding sports medicine examinations in children, adolescents and young athletes came into force. The publication presents in detail the current scope of tests and the frequency of required medical examinations necessary to obtain medical certificates qualify- ing patients to practice sports. The publication also presents the Regulation of the Minister of Health on the required qualifications of doctors authorized to issue medical certificates to athletes. It is very important to properly assess the health of potential and current athletes to ensure their safety while participating in sports competitions. There are diseases that increase the risk of sudden cardiac death which doctors should keep in mind when qualifying athletes for competition. The publication draws attention to the underestimated role of echocardiography and electrocardiographic stress testing.
Women receive 225-300 IU s.c. FSH, and a GnRH antagonist from day 6 of FSH treatment at the dose of 0.25 mg per day until the triggering day. The GnRH antagonist in group 2 is injected each time immediately after the injection of FSH.
PURPOSE:To provide a water-based enteric coating agent having high handleability, dispersibility, film-forming property, safety, etc., by dispersing a specific amount of a carboxyl-containing cellulose derivative in a mixture of a lower alcohol, water and ammonia. CONSTITUTION:A mixed solvent composed of a 1-3C lower alcohol, water and ammonia is mixed with 2-20wt% of a carboxyl-containing cellulose derivative (e.g. cellulose acetate phthalate, carboxymethyl ethylcellulose, etc.) to obtain the objective water-based enteric coating agent. The ratio of ammonia in the whole solvent is 0.01-1wt%, preferably 0.03-0.3wt%. The lower alcohol is principally ethyl alcohol from the view-point of safety. It has excellent dispersibility, film- forming property, yield, and safety compared with conventional water-based enteric coating agents.
The standard care group will not be offered the intervention until the end of the study at 12 months. Participants in this group will be encouraged to continue with their usual lifestyle.
All the subjects will be checked-in into the clinical study facility on Day -1, the day prior to dosing. The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study. There will be a washout period of three days between each period. The subjects will continue to remain in the clinical facility for the entire duration of the study (completion of three periods in the study), including wash out period. Prior to check out procedure, detailed clinical examination will be done to confirm that subject has no safety issues.
The first three eligible enrolled patients will be treated with initial dosing of HYML-122 400mg bid daily and cytarabine 100mg/m2 intravenously by using "3+3" escalating design to explore RP2D. the Data Monitoring Committee (DMC) will evaluate the safety, efficacy and PK data of the phase 1 subjects and establish the combined regimen recommended dose. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgement of the investigator, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet 1 of the discontinuation criteria, whichever occurs first.
Pancreatic fistula is a highly morbid complication of pancreatitis. External pancreatic fistulas result when pancreatic secretions leak externally into the percutaneous drains or external wound (following surgery) due to the communication of the peripancreatic collection with the main pancreatic duct (MPD). Internal pancreatic fistulas include communication of the pancreatic duct (directly or via intervening collection) with the pleura, pericardium, mediastinum, peritoneal cavity, or gastrointestinal tract. Cross-sectional imaging plays an essential role in the management of pancreatic fistulas. With the help of multiplanar imaging, fistulous tracts can be delineated clearly. Thin computed tomography sections and magnetic resonance cholangiopancreatography images may demonstrate the communication between MPD and pancreatic fluid collections or body cavities. Endoscopic retrograde cholangiography (ERCP) is diagnostic as well as therapeutic. In this review, we discuss the imaging diagnosis and management of various types of pancreatic fistulas with the aim to sensitize radiologists to timely diagnosis of this critical complication of pancreatitis.
The present invention relates to a medical composition which is used for treating children's external-contracted wind-heat cough and contains extract products of traditional Chinese medicines. The medical composition is mainly prepared from mulberry leaf, mint, bitter apricot seed, platycodon root, white peony alba, orange fruit, tatarian aster root, dried orange peel and licorice root, and is mainly used for diffusing the lung qi and secondarily used for the governing purification of the lung qi. The medical composition has the functions of relieving cough, eliminating phlegm and resisting inflammation, and treats both the manifestation and the root cause of diseases. The treating effect is improved and consolidated. The prescription combination has no toxic or side effect, and does not influence the children's growth and development. The present invention also comprises an industrial-production preparing method thereof.
Auditory verbal hallucinations (AVH) are experienced by up to 80% of patients diagnosed with schizophrenia, where they can cause significant occupational and social impairment. Current treatments are incompletely effective. Around 25-30% of AVH are refractory to antipsychotic drugs, and cognitive behavioural therapy only shows a small-medium effect size. Initially promising studies of neurostimulation have shown smaller effect sizes as better controlled trials have been conducted. There is hence the need for innovative new treatments. One potential option is neurofeedback training. The primary objective of study is to perform a randomized, controlled, rater-blinded pilot trial (n=40) of EEG neurofeedback for AVH in patients with treatment-resistant schizophrenia, to assess trial process, which will then inform a future definitive trial. The secondary objective is to calculate a 95% confidence interval that will allow interpretation of statistical difference between neurofeedback and treatment-as-usual groups to assess neurofeedback for reducing auditory verbal hallucinations. Participants will be randomly allocated to either a neurofeedback (plus treatment-as-usual) or treatment-as-usual alone condition. Neurofeedback will employ Z-score based LORETA (Low Resolution Brain Electromagnetic Tomography). After a baseline assessment, twenty sessions of personalized neurofeedback training will be delivered over a period of approximately four months. This is the first registered trial of EEG neurofeedback for hallucinations. The primary focus of the pilot trial is on feasibility. However, a 95% confidence interval will be determined for the difference on PSYRATS-AH and AHRS scores between neurofeedback and treatment-as-usual to help inform a future definitive trial.
At present, the application of POX (pulse oximetry) in screening major CHD (congenital heart disease ) has been legislated in the United States. In China, the two indicators of POX plus auscultation of heart murmur for screening major CHD have also been promoted as national standards. There are differences in the POX range of newborns at different altitude areas, so the threshold of POX screening based on sea-level areas is not applicable to low, medium and high altitude areas. While the normal range of POX at different altitude areas has not been studied in detail, so the current screening strategy can only be used in sea-level areas, but not benefit newborns in low, medium and high altitude areas. In order to apply major CHD screening strategy better to cover the newborns all over the country, we need to clarify the range of POX at different altitude areas of China and make sure the threshold of POX in major CHD screening. We plan to carry out a multicenter study on the normal POX value range of healthy and asymptomatic term newborns 6-72 hours after delivery in medical centers with altitude of 500-1000; 1000-2000; 2000-3000; 3000-4000 and above 4000 meters. And compare the POX value at different altitude areas with that of newborns delivered in the maternity hospitals at sea level. And measure the POX value of newborns with major CHD in the same way. POX screening thresholds will be obtained at different altitude areas. We will test the hypothesis that POX of healthy newborns at different altitude areas is lower than that of healthy newborns at sea level, and POX threshold of major CHD screening is lower than that of sea level.
B-cell lymphomas reveal surface immunoglobin (immunoglobin) containing unique idiotypic (idiotype) determiners which can be exploited as specialised tumour markers. The subject has produced muscular monoclonal antibodies (MAbs) in reaction to the idiotype marker, produced by 67 patients with small cleaved cell, low level lymphomas. Except for the, 199 monoclonal cleaved cell antibodies, 47 (24 percent) were found to react to immunoglobin group normal human serum at concentrations ranging from 0.6 μg/ml to 160 μg/ml (micrograms/cc.) Of these 40 monoclonal antibodies, 90 percent cross-reacted with an idiotype produced in normal serum at levels lower than 50 μg/ml. Thirty two of these anti-idiotypes were directed toward the shared idiotype, expressed in other lymphoma cells of patients. The frequent expression of shared idiotypes was determined by each antibody ranging from 0.26 percent to 3.9 percent of tested B-cell lymphomas. A group of five anti-idiotype antibodies reacted with 80 percent of lymphomas associated with AIDS. Based on reactivity with these monoclonal antibodies, tumours could be classified into specific families. Globally, the 32 monoclonal antibodies reacted with the entire 108 of 332 B-cell lymphoma cases (32.5 percent) including 35 of 116 small cleaved cell type lymphomas (30 percent). Many of these anti-shared idiotypes reacted with more than one histopathological lymphoma subtype. Anti-idiotypes have been used in diagnosis and therapy of B-cell lymphomas. The subject additionally revealed at least seven anti-shared idiotype antibodies reacting with antibodies, 16.6 and RF, for example. Development of a library of anti-idiotypes reactive with shared idiotypes will facilitate these clinical studies, obviating the need to culture the usual hybridomas for each patient.
Facial expressions are important in pain recognition in horses, but current observation-based pain scales remain subjective. A promising technique to quantitatively measure subtle changes in expression patterns, including changes invisible to the human eye, is surface electromyography (sEMG). To achieve high-quality and reliable sEMG signals, unilateral placement of bipolar electrodes is required in relation to the motor endplates (MEP). We aimed to localize the nerve entry points (NEPs; where the nerve branch first pierced the muscle belly) and the direction of the terminal nerve endings to estimate MEP locations of the innervating nerves in five equine facial muscles involved in pain expression. Three cadaveric Dutch Warmblood horse heads were dissected to identify the NEPs in the musculi caninus, levator anguli oculi medialis, nasolabialis, masseter and zygomaticus. These points were marked with pins and measured in relation to a reference line between two anatomical landmarks near the origin and insertion of the respective muscle. Relative distances were calculated from the most caudally situated landmark. NEPs were located at 33%-38% (caninus), 69%-86% (levator anguli oculi medialis) and 0%-18% (zygomaticus) from the caudal landmark. The nasolabialis showed two innervations zones. Its NEPs were located at 47%-72% (dorsal muscle branch) and 52%-91% (ventral branch). All terminal nerve endings were found to run in rostral direction. The masseter showed numerous NEPs diffusely spread within the muscle belly. Therefore, calculation of relative positions was not performed. These results could form the basis for feasibility studies and standardization of bipolar electrode positioning in vivo to measure facial muscle activity patterns in horses.
The invention describes a new anti-tumor preparation in the form of stable nanoparticles made from a biodegradable polymer and comprising 2 cytostatic agents having different mechanisms of action and a vector molecule for targeted delivery of the particles to tumor tissues. The medicinal composition also preferably contains a surfactant and a cryoprotectant. Vincristine and methotrexate are used as the cytostatics, and the C-terminal domain of alpha-fetoprotein is used as the vector molecule for targeted delivery of the particles to tumor tissues. The invention provides a substantial increase in the effectiveness and safety of the indicated cytostatics. A drug product consists of a sample of a finished form of the preparation that meets the usage standards for sterile dosage forms for human use with regard to parameters for dissolution, uniformity, pyrogenicity, endobacterial toxin content, stability, and sterility. Therapeutic indications of the preparation include acute and chronic myeloid leukemia, lymphoblastic leukemia and other soft tissue oncological diseases.
Reduced sense of smell is a common symptom in patients with chronic rhinosinusitis (CRS). Although it is often under-diagnosed by healthcare providers, reduced sense of smell can have a substantial negative impact on patient's quality of life as measured by health-related quality of life (HRQoL) assessments and patient-reported outcomes. This narrative review describes current smell loss diagnosis and management guidelines in CRS, and the relationship between smell loss and CRS. Reduced sense of smell can be an indication of CRS disease severity in patients with (CRSwNP) and without nasal polyps (CRSsNP), and recovery of smell can be an indicator of successful CRS treatment. The current first-line therapeutic options for smell loss are intranasal corticosteroids and nasal irrigation, and second-line therapeutic options include systemic steroids and surgery. Shared decision-making between patient, caregiver, and healthcare provider is important when choosing the most appropriate CRS treatment option. Emerging biologic therapies that target type 2 inflammation signaling pathways, such as dupilumab, omalizumab, and mepolizumab, have been shown to improve smell and taste in randomized controlled trials of patients with CRSwNP.A graphical abstract and video abstract are available with this article.
The High Risk group will consist of 250 women with a positive cfDNA screen reported by a Clinical Laboratory Improvement Amendments (CLIA)-approved commercial laboratory, and who present for consideration of a confirmatory diagnostic test, (i.e., CVS or amniocentesis). Consenting women will provide samples for SmartNIPT testing.
A method and system for producing polarized 129Xe gas in an economical manner, allowing the polarized 129Xe gas to be used commercially in research and clinical applications. The production system of the present invention includes a holding tank for holding an unpolarized xenon gas/nitrogen gas mixture. The holding tank is in communication with a temperature controlled polarization chamber. A wide spectrum high power light source such as a diode laser array is in communication with the polarization chamber. The alkali metal vapor is optically pumped by the light source. The polarization chamber, which contains a given quantity of an alkali metal and its associated vapor, receives the gaseous mixture from the holding tank. The optically pumped alkali metal vapor atoms then collide with the xenon gas atoms, thus polarizing the xenon atoms. The entire gaseous mixture expands out of the polarization chamber into a device that separates the alkali metal vapor atoms from the polarized 129Xe atoms. The polarized 129Xe atoms are then controllably output to a system/user interface for application purposes.
Endodontic sealant compositions and methods for sealing a root canal (12) using sealant (30) or other filling materials. The compositions include one or more resins that promote adhesion to hydrophilic dental tissues. Examples include alkyl methacrylates and derivatives thereof, such as alkylamino methacrylates and oxyphosphoro methacrylates. The compositions include a radio opacifying agent, so that they may be seen using X-rays, and one or more polymerization initiators to effect curing, typically both chemical and photo initiators to yield a dual cure sealant composition. The compositions are introduced into the root canal (12) using a narrow cannula (26-Fig.2) coupled to a high pressure hydraulic delivery (24-Fig.2). Additional pressure may be applied to the sealant compositions (30) using a syringe-like plunger (36, 42) introduced within a cylindrical access hole (34) drilled through the crown of the tooth (10). A curing lamp may be used to cure the top layer of the sealant composition to provide a rigid bonding surface to which a composite resin can chemically bond or adhere.
NEW MATERIAL:(2Z,4E)-2,4,11-dodecatrienal of formula Ia or (2Z,4Z)-2,4,11- dodecatrienal of formula Ib. USE:A component of perfumery composition. It has strong fragrance. The fragrant note depends upon the steric structure, and the compound of formula Ia has refreshing sweet citrus fragrance while the compound of formula Ib has the fragrance of mandarin orange oil. It is used singly or in combination with other perfumery components, as an additive for domestic goods such as perfume, aromatic agent, cosmetics, soap, detergent, shampoo, hair rinse, etc., or additive for foods, hygienic goods, pharmaceuticals, etc. PREPARATION:The compound of formula Ia or formula Ib can be produced by (1) converting the vinyl phosphonium salt of formula II to phosphorus ylide with LiOEt in tetrahydrofuran under N2 gas stream, (2) subjecting to Wittig reaction with 2E(or 2Z)-2,9-decadienal to obtain diethyl acetal of formula III and, (3) treating the acetal with an acid after purification.
Capecitabine is a drug recommended for adjuvant therapy in early breast cancer. The key to improving the prognosis of early breast cancer is to ensure that adequate treatment is sufficient. Hand foot syndrome Hand foot syndrome (HFS) is the most common and specific side effect of capecitabine, in which the incidence of grade 2 / 3 HFS requiring treatment is as high as 17-36%. At present, there is no specific drug for the treatment of HFS, and capecitabine must be reduced or stopped in case of grade 2 / 3 HFS. The guidelines also do not recommend standard drugs for the prevention of HFS. Mecobalamin is a derivative of vitamin B12, which can improve autonomic nervous system After symptoms and repair of small neuropathy, its clinical indication is the treatment of peripheral neuropathy.

A multicenter, randomized, placebo-controlled, double-blind, phase III clinical trial will be conducted to explore the efficacy and safety of mecobalamin in the prevention of 2/3 HFS in patients with early breast cancer. 234 patients will be enrolled and will be randomized into mecobalamin group and placebo group at the ration of 1:1. The incidence of grade 2 / 3 HFS in the experimental group and the control group will be observed. This study is expected to provide evidence for clinical prevention of hand foot syndrome, improve clinical treatment guidelines for early breast cancer, and provide reference for other antitumor drugs for hand foot syndrome.
The efficacy of sodium phenylacetate and sodium benzoate injection in improving patient survival of acute hyperammonemic episodes was demonstrated in an analysis of 316 patients (1,045 episodes of hospitalization) treated between 1981 and 2003. 

The demographic characteristics and diagnoses of the patient population are shown in Table 3.

On admission to the hospital, patients with hyperammonemia and a suspected or confirmed urea cycle disorder (UCD) diagnosis were treated with a bolus dose of 0.25 g/kg (or 5.5 g/m2) sodium phenylacetate + 0.25 g/kg (or 5.5 g/m2) sodium benzoate over a period of 90 minutes to 6 hours, depending on the specific UCD. Infusions also contained arginine; the dose of arginine depended on the specific UCD. After completion of the bolus dose, maintenance infusions of the same dose over 24 hours were continued until the patient was no longer hyperammonemic or oral therapy could be tolerated. The mean (SD) duration of treatment was 4.6 (6.45) days per episode, and ranged from 1 to 72 days. 

Survival was substantially improved after sodium phenylacetate and sodium benzoate injection treatment compared with historical values (estimated 14% 1-year survival rate with dietary therapy alone) and with dialysis (estimated 43% survival of acute hyperammonemia). 

Eighty percent of patients (252 of 316) survived their last episode. Of the 64 patients who died, 53 (83%) died during their first hyperammonemic episode. Of the 104 neonates (< 30d) treated with sodium phenylacetate and sodium benzoate injection, 34 (33%) died during the first hyperammonemic episode. 

Ammonia levels decreased from very high levels (>4 times the upper limit of normal [ULN]) to lower levels in 91% of episodes after treatment. In patients responding to therapy, mean ammonia concentrations decreased from 200.9 µmol/L at hour zero to 101.6 µmol/L within four hours of initiation of sodium phenylacetate and sodium benzoate injection therapy and were maintained. Hemodialysis is recommended for those patients whose plasma ammonia levels fail to fall below 150 µmol/L or by more than 40% within 4 to 8 hours after receiving sodium phenylacetate and sodium benzoate injection. A shift from high (≤ 4 times ULN) to very high (> 4 times ULN) levels was observed in only 4% of the episodes. 

Overall, investigators rated neurological status as improved, much improved, or the same in 93% of episodes, and overall status in response to treatment as improved, much improved, or the same in 97% of episodes. Recovery from coma was observed in 97% of episodes where coma was present at admission (111 of 114 episodes).
Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to Arm II. Patients undergo an x-ray, CT scan, MRI, bone scan, and/or PET scan as well as a biopsy and blood sample collection throughout the trial. Patients may also undergo a bone marrow aspiration and biopsy on study.
As the indications for endoscopic skull base approaches have increased, so has the need for more versatile vascularized flaps for skull base reconstruction. Here, we describe a novel lateral based nasopharyngeal flap (LNPF). Two cadaver heads were dissected to elucidate flap anatomy, dimensions, and technique. A retrospective review was performed on two cases where LNPF was used to repair CSF leaks in the nasopharyngeal area, and outcomes reported. The LNPF is an ascending pharyngeal artery myomucosal flap that includes the nasopharyngeal mucosa and the superior pharyngeal constrictor muscle. The flap was 1.2 × 2.2 cm in greatest dimensions. The LNPF was used for salvage CSF leak repair in two cases: one clival and one tubal. Both patients had resolution of leak at 7 months follow-up. The LNPF is a novel flap with reconstruction potential for the nasopharynx, including the lower clivus and the eustachian tube.